Monoclonal Antibody Targeting of Liposomes to Mouse Lung in Vivo

Brenda J. Hughes, Stephen Kennel, Leaf Huang, Ray Lee

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

A monoclonal antibody (MoAb), 273-34A, specifically binds to an epitope expressed almost exclusively on capillary endothelial cells of the lung. Within 15 min after i.v. injection, approximately 80 to 85% of the injected radioiodinated MoAb 273-34A accumulates in the lung. Approximately 90 to 95% of the recovered dose is found in the lung for up to 1 week postinjection. Ratios of MoAb 273-34A to a nonspecific, irrelevant MoAb 135-14 are 250 to 285 times higher in the lung than in the serum. When 273-34A was coupled with palmitic acid and incorporated into liposomes, the amount of 125I-labeled liposomes recovered per g of tissue was 12 times higher in the lung than in the liver at 15 min postinjection, and 22 times higher at 5 h postinjection. At 24 h postinjection the amount of liposomes per gram of lung tissue was still 6.0 times the amount per gram of liver tissue. Liposomes conjugated to MoAb 273-34A locate in the lung 20 and 15 times better than do liposomes conjugated to the nonspecific MoAb 135-14 at 15 min and 24 h postinjection, respectively. The results indicate that this immunoliposome system could be used as a model for enhanced drug delivery to the lung. The potential use for delivering anticancer drugs for therapy of lung tumors is discussed.

Original languageEnglish (US)
Pages (from-to)6214-6220
Number of pages7
JournalCancer Research
Volume49
Issue number22
StatePublished - Nov 5 1989
Externally publishedYes

Fingerprint

Liposomes
Monoclonal Antibodies
Lung
Palmitic Acid
Liver
Epitopes
Endothelial Cells
Drug Therapy
Injections
Serum
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hughes, B. J., Kennel, S., Huang, L., & Lee, R. (1989). Monoclonal Antibody Targeting of Liposomes to Mouse Lung in Vivo. Cancer Research, 49(22), 6214-6220.

Monoclonal Antibody Targeting of Liposomes to Mouse Lung in Vivo. / Hughes, Brenda J.; Kennel, Stephen; Huang, Leaf; Lee, Ray.

In: Cancer Research, Vol. 49, No. 22, 05.11.1989, p. 6214-6220.

Research output: Contribution to journalArticle

Hughes, BJ, Kennel, S, Huang, L & Lee, R 1989, 'Monoclonal Antibody Targeting of Liposomes to Mouse Lung in Vivo', Cancer Research, vol. 49, no. 22, pp. 6214-6220.
Hughes, Brenda J. ; Kennel, Stephen ; Huang, Leaf ; Lee, Ray. / Monoclonal Antibody Targeting of Liposomes to Mouse Lung in Vivo. In: Cancer Research. 1989 ; Vol. 49, No. 22. pp. 6214-6220.
@article{4dada6a639794e4b836be57e0690df06,
title = "Monoclonal Antibody Targeting of Liposomes to Mouse Lung in Vivo",
abstract = "A monoclonal antibody (MoAb), 273-34A, specifically binds to an epitope expressed almost exclusively on capillary endothelial cells of the lung. Within 15 min after i.v. injection, approximately 80 to 85{\%} of the injected radioiodinated MoAb 273-34A accumulates in the lung. Approximately 90 to 95{\%} of the recovered dose is found in the lung for up to 1 week postinjection. Ratios of MoAb 273-34A to a nonspecific, irrelevant MoAb 135-14 are 250 to 285 times higher in the lung than in the serum. When 273-34A was coupled with palmitic acid and incorporated into liposomes, the amount of 125I-labeled liposomes recovered per g of tissue was 12 times higher in the lung than in the liver at 15 min postinjection, and 22 times higher at 5 h postinjection. At 24 h postinjection the amount of liposomes per gram of lung tissue was still 6.0 times the amount per gram of liver tissue. Liposomes conjugated to MoAb 273-34A locate in the lung 20 and 15 times better than do liposomes conjugated to the nonspecific MoAb 135-14 at 15 min and 24 h postinjection, respectively. The results indicate that this immunoliposome system could be used as a model for enhanced drug delivery to the lung. The potential use for delivering anticancer drugs for therapy of lung tumors is discussed.",
author = "Hughes, {Brenda J.} and Stephen Kennel and Leaf Huang and Ray Lee",
year = "1989",
month = "11",
day = "5",
language = "English (US)",
volume = "49",
pages = "6214--6220",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Monoclonal Antibody Targeting of Liposomes to Mouse Lung in Vivo

AU - Hughes, Brenda J.

AU - Kennel, Stephen

AU - Huang, Leaf

AU - Lee, Ray

PY - 1989/11/5

Y1 - 1989/11/5

N2 - A monoclonal antibody (MoAb), 273-34A, specifically binds to an epitope expressed almost exclusively on capillary endothelial cells of the lung. Within 15 min after i.v. injection, approximately 80 to 85% of the injected radioiodinated MoAb 273-34A accumulates in the lung. Approximately 90 to 95% of the recovered dose is found in the lung for up to 1 week postinjection. Ratios of MoAb 273-34A to a nonspecific, irrelevant MoAb 135-14 are 250 to 285 times higher in the lung than in the serum. When 273-34A was coupled with palmitic acid and incorporated into liposomes, the amount of 125I-labeled liposomes recovered per g of tissue was 12 times higher in the lung than in the liver at 15 min postinjection, and 22 times higher at 5 h postinjection. At 24 h postinjection the amount of liposomes per gram of lung tissue was still 6.0 times the amount per gram of liver tissue. Liposomes conjugated to MoAb 273-34A locate in the lung 20 and 15 times better than do liposomes conjugated to the nonspecific MoAb 135-14 at 15 min and 24 h postinjection, respectively. The results indicate that this immunoliposome system could be used as a model for enhanced drug delivery to the lung. The potential use for delivering anticancer drugs for therapy of lung tumors is discussed.

AB - A monoclonal antibody (MoAb), 273-34A, specifically binds to an epitope expressed almost exclusively on capillary endothelial cells of the lung. Within 15 min after i.v. injection, approximately 80 to 85% of the injected radioiodinated MoAb 273-34A accumulates in the lung. Approximately 90 to 95% of the recovered dose is found in the lung for up to 1 week postinjection. Ratios of MoAb 273-34A to a nonspecific, irrelevant MoAb 135-14 are 250 to 285 times higher in the lung than in the serum. When 273-34A was coupled with palmitic acid and incorporated into liposomes, the amount of 125I-labeled liposomes recovered per g of tissue was 12 times higher in the lung than in the liver at 15 min postinjection, and 22 times higher at 5 h postinjection. At 24 h postinjection the amount of liposomes per gram of lung tissue was still 6.0 times the amount per gram of liver tissue. Liposomes conjugated to MoAb 273-34A locate in the lung 20 and 15 times better than do liposomes conjugated to the nonspecific MoAb 135-14 at 15 min and 24 h postinjection, respectively. The results indicate that this immunoliposome system could be used as a model for enhanced drug delivery to the lung. The potential use for delivering anticancer drugs for therapy of lung tumors is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0024352945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024352945&partnerID=8YFLogxK

M3 - Article

VL - 49

SP - 6214

EP - 6220

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 22

ER -